SLC27A5
Basic information
Region (hg38): 19:58479512-58512413
Links
Phenotypes
GenCC
Source:
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the SLC27A5 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 14 | 22 | 40 | |||
missense | 111 | 123 | ||||
nonsense | 0 | |||||
start loss | 1 | |||||
frameshift | 4 | |||||
inframe indel | 3 | |||||
splice donor/acceptor (+/-2bp) | 1 | |||||
splice region | 3 | 1 | 4 | |||
non coding | 12 | |||||
Total | 0 | 0 | 139 | 34 | 11 |
Variants in SLC27A5
This is a list of pathogenic ClinVar variants found in the SLC27A5 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
19-58479665-G-A | not specified | Uncertain significance (Nov 04, 2022) | ||
19-58479682-T-C | not specified | Uncertain significance (May 21, 2024) | ||
19-58479936-C-T | not specified | Uncertain significance (Dec 20, 2023) | ||
19-58479998-G-A | not specified | Uncertain significance (Sep 03, 2024) | ||
19-58480005-G-A | not specified | Uncertain significance (Sep 23, 2023) | ||
19-58480017-C-G | not specified | Uncertain significance (Jul 22, 2024) | ||
19-58480176-G-T | not specified | Uncertain significance (Dec 02, 2024) | ||
19-58480226-G-T | Short stature | Uncertain significance (Nov 18, 2001) | ||
19-58480268-A-G | not specified | Uncertain significance (Nov 12, 2021) | ||
19-58480278-C-A | not specified | Uncertain significance (Dec 11, 2023) | ||
19-58480286-C-A | not specified | Uncertain significance (Sep 04, 2024) | ||
19-58480343-C-A | not specified | Uncertain significance (Sep 23, 2023) | ||
19-58480356-C-T | Likely benign (Jan 01, 2023) | |||
19-58480389-G-A | not specified | Uncertain significance (Aug 14, 2023) | ||
19-58480391-G-A | not specified | Uncertain significance (Apr 08, 2022) | ||
19-58480391-G-C | not specified | Uncertain significance (Feb 23, 2023) | ||
19-58480392-G-C | not specified | Uncertain significance (Aug 17, 2022) | ||
19-58480401-G-A | Short stature | Pathogenic (Nov 18, 2001) | ||
19-58480428-G-A | not specified | Uncertain significance (Jan 23, 2023) | ||
19-58480428-G-T | not specified | Uncertain significance (Oct 18, 2021) | ||
19-58480434-A-G | not specified | Uncertain significance (Nov 09, 2022) | ||
19-58480437-C-T | not specified | Uncertain significance (Aug 03, 2022) | ||
19-58480464-G-A | not specified | Uncertain significance (Feb 28, 2024) | ||
19-58480475-G-A | EBV-positive nodal T- and NK-cell lymphoma | Likely benign (-) | ||
19-58480524-A-G | not specified | Uncertain significance (Aug 15, 2023) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
SLC27A5 | protein_coding | protein_coding | ENST00000263093 | 10 | 32902 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
8.37e-15 | 0.0664 | 125582 | 0 | 166 | 125748 | 0.000660 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 0.399 | 401 | 424 | 0.946 | 0.0000258 | 4322 |
Missense in Polyphen | 118 | 141.68 | 0.83288 | 1609 | ||
Synonymous | 1.43 | 160 | 185 | 0.866 | 0.0000109 | 1539 |
Loss of Function | 0.694 | 24 | 28.0 | 0.858 | 0.00000144 | 281 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.00169 | 0.00157 |
Ashkenazi Jewish | 0.0000995 | 0.0000992 |
East Asian | 0.000558 | 0.000544 |
Finnish | 0.00135 | 0.00134 |
European (Non-Finnish) | 0.000600 | 0.000589 |
Middle Eastern | 0.000558 | 0.000544 |
South Asian | 0.000760 | 0.000686 |
Other | 0.000491 | 0.000489 |
dbNSFP
Source:
- Function
- FUNCTION: Acyl-CoA synthetase involved in bile acid metabolism. Proposed to catalyze the first step in the conjugation of C24 bile acids (choloneates) to glycine and taurine before excretion into bile canaliculi by activating them to their CoA thioesters. Seems to activate secondary bile acids entering the liver from the enterohepatic circulation. In vitro, also activates 3-alpha,7- alpha,12-alpha-trihydroxy-5-beta-cholestanate (THCA), the C27 precursor of cholic acid deriving from the de novo synthesis from cholesterol. {ECO:0000269|PubMed:10749848, ECO:0000269|PubMed:11980911}.;
- Pathway
- Insulin resistance - Homo sapiens (human);Bile secretion - Homo sapiens (human);Primary bile acid biosynthesis - Homo sapiens (human);PPAR signaling pathway - Homo sapiens (human);27-Hydroxylase Deficiency;Bile Acid Biosynthesis;Congenital Bile Acid Synthesis Defect Type II;Cerebrotendinous Xanthomatosis (CTX);Zellweger Syndrome;Familial Hypercholanemia (FHCA);Congenital Bile Acid Synthesis Defect Type III;Farnesoid X Receptor Pathway;Nuclear Receptors Meta-Pathway;PPAR signaling pathway;Metabolism of lipids;Metabolism;Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol;Synthesis of bile acids and bile salts via 24-hydroxycholesterol;Synthesis of bile acids and bile salts;Recycling of bile acids and salts;Bile acid and bile salt metabolism;Metabolism of steroids;Bile acid biosynthesis;bile acid biosynthesis, neutral pathway;Arachidonic acid metabolism
(Consensus)
Recessive Scores
- pRec
- 0.150
Intolerance Scores
- loftool
- 0.851
- rvis_EVS
- 0.29
- rvis_percentile_EVS
- 71.6
Haploinsufficiency Scores
- pHI
- 0.0742
- hipred
- N
- hipred_score
- 0.146
- ghis
- 0.460
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- S
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.810
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Slc27a5
- Phenotype
- homeostasis/metabolism phenotype; growth/size/body region phenotype; adipose tissue phenotype (the observable morphological and physiological characteristics of mammalian fat tissue that are manifested through development and lifespan); behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); liver/biliary system phenotype;
Gene ontology
- Biological process
- very long-chain fatty acid metabolic process;long-chain fatty acid metabolic process;triglyceride mobilization;bile acid biosynthetic process;bile acid metabolic process;bile acid and bile salt transport;plasma membrane long-chain fatty acid transport;ketone body biosynthetic process
- Cellular component
- endoplasmic reticulum;endoplasmic reticulum membrane;basal plasma membrane;integral component of endoplasmic reticulum membrane;protein-containing complex
- Molecular function
- long-chain fatty acid-CoA ligase activity;long-chain fatty acid transporter activity;ATP binding;fatty acid transmembrane transporter activity;very long-chain fatty acid-CoA ligase activity;protein-containing complex binding;cholate-CoA ligase activity